{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"25.0"},{"groupId":"OG002","value":"40.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"75.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"50.0"},{"groupId":"OG007","value":"33.3"},{"groupId":"OG008","value":"33.3"},{"groupId":"OG009","value":"33.3"},{"groupId":"OG010","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants with a CR, PR, or stable disease (SD), determined by investigator assessment of radiographic disease assessments per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. SD: no change in target lesions to qualify for CR, PR, or PD.","groups":[{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 milligrams (mg) every 2 weeks (Q2W) beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as intravenous (IV) infusions.","id":"OG000","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG001","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG002","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG003","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kilogram (kg) every 6 weeks (Q6W) beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG004","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG005","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG006","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG007","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG008","title":"Phase 1, Safety Expansion: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG009","title":"Phase 1, Safety Expansion: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG010","title":"Phase 1, Safety Expansion: INCAGN01949 350 mg + Nivolumab 240 mg"}],"paramType":"NUMBER","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"up to 15.6 months","title":"Phase 1: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}